Clinical Trial Update: Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating tazemetostat for recurrent ovarian or endometrial cancers; the study is currently not recruiting and results were po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Endometrial Endometrioid Adenocarcinoma
• Ovarian Cancer
• Ovarian Clear Cell Carcinoma
• Ovarian Endometrioid Adenocarcinoma

Drugs mentioned

• Tazverik (tazemetostat) (tazemetostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-03-06